Decelerating Decay of Latently Infected Cells during Prolonged Therapy for Human Immunodeficiency Virus Type 1 Infection
AUTOR(ES)
Müller, Viktor
FONTE
American Society for Microbiology
RESUMO
Antiviral therapy induces a rapid drop in human immunodeficiency virus type 1 viremia, but the decline of virus levels decelerates over time. Mathematical modeling demonstrates that the source of residual virus production might be a single compartment of latently infected cells with an extended distribution of activation rates.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=136417Documentos Relacionados
- CD14 is involved in control of human immunodeficiency virus type 1 expression in latently infected cells by lipopolysaccharide.
- Alternative splice acceptor utilization during human immunodeficiency virus type 1 infection of cultured cells.
- P Glycoprotein in Human Immunodeficiency Virus Type 1 Infection and Therapy
- Both R5 and X4 Human Immunodeficiency Virus Type 1 Variants Persist during Prolonged Therapy with Five Antiretroviral Drugs
- Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy.
